Peptide questions · Semaglutide (oral)

Semaglutide (oral) side effects: what studies and users report

Reviewed Evidence: EstablishedPublished by PepVault

The side effects most commonly reported for semaglutide (oral) are nausea, abdominal pain and diarrhea, among 6 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: Both tablet labels carry the GLP-1 class boxed warning for thyroid C-cell tumors seen in rodents, plus the weekly shot's pancreatitis, gallbladder and low-blood-sugar (with insulin or sulfonylureas) warnings.

What is commonly reported with semaglutide (oral)

  • Nausea
  • Abdominal pain
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other metabolic & GLP-1 compounds the library lists it for
EffectAlso listed for (of 24)
Nausea21: Semaglutide, Tirzepatide, Retatrutide, Liraglutide and 17 more
Abdominal pain7: Tirzepatide, Retatrutide, Dulaglutide, Setmelanotide and 3 more
Diarrhea20: Semaglutide, Tirzepatide, Retatrutide, Liraglutide and 16 more
Decreased appetite9: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 5 more
Vomiting18: Semaglutide, Tirzepatide, Retatrutide, Liraglutide and 14 more
Constipation13: Semaglutide, Tirzepatide, Retatrutide, Liraglutide and 9 more
A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Track Semaglutide (oral) in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which semaglutide (oral) side effects the metabolic & GLP-1 group shares

Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on semaglutide (oral)’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is semaglutide (oral)’s own.

What the semaglutide (oral) safety notes say

The library’s safety note

Both tablet labels carry the GLP-1 class boxed warning for thyroid C-cell tumors seen in rodents, plus the weekly shot's pancreatitis, gallbladder and low-blood-sugar (with insulin or sulfonylureas) warnings. These are label findings; review them with your clinician.

The library’s interaction note

The Wegovy label advises against taking its tablets with other semaglutide products or any other GLP-1 drug.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the semaglutide (oral) reports come from

The library rates the evidence on semaglutide (oral) as established: clinical trials or FDA-approved use exist.

Our 6 study pages on semaglutide (oral): 6 randomized trials.

So semaglutide (oral) has controlled trials in people to set its listed effects against.

What our semaglutide (oral) study pages report on safety

Semaglutide (oral) did not slow early Alzheimer's in evoke trials

Randomized trial, human, 2026: Side effects that came up during treatment were seen in 1729 (91.2%) of 1896 people taking semaglutide and 1613 (84.8%) of 1902 taking placebo, and investigators linked five deaths to treatment: one on semaglutide and four on placebo. In these two large trials, oral semaglutide did not slow early Alzheimer's disease, and its safety was in line with what has been seen in its other uses.

Semaglutide (oral): fewer major heart events than placebo in SOUL

Randomized trial, human, 2025: The key secondary outcomes, including a combined measure of major kidney disease events, showed no significant gap between groups, and serious adverse events were 47.9% with oral semaglutide versus 50.3% with placebo, with gastrointestinal disorders at 5.0% and 4.4%. For people with type 2 diabetes and heart or kidney disease, this large trial found daily oral semaglutide lowered the risk of major heart events compared with placebo, with no rise in serious side effects.

Semaglutide (oral): heart risk not higher than placebo in PIONEER 6

Randomized trial, human, 2019: Stomach and gut side effects that led people to stop treatment were more common with oral semaglutide. More people on it stopped treatment because of stomach and gut side effects.

Questions people ask

What are the side effects of semaglutide (oral)?

The side effects most commonly reported for semaglutide (oral) are nausea, abdominal pain and diarrhea, among 6 the library lists; the library’s evidence on it includes controlled trials in people.

Do semaglutide (oral)’s side effects come from human studies?

The library rates the evidence on semaglutide (oral) as established, and the library’s evidence on it includes controlled trials in people.

Which semaglutide (oral) side effects are its own?

None: each effect the library lists for semaglutide (oral) is listed for at least one other metabolic & GLP-1 compound too.

Does semaglutide (oral) interact with other medicines?

The library’s interaction note on semaglutide (oral) begins: The Wegovy label advises against taking its tablets with other semaglutide products or any other GLP-1 drug.

More on Semaglutide (oral)

Track it in the app

PepVault for iPhone

Track Semaglutide (oral) in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo